Navigation Links
Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
Date:3/23/2009

al biology program that has delivered multiple co- crystal structures of JAK2 bound with inhibitors. Cytopia has also developed an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform.

Cytopia is developing a suite of JAK2 inhibitors for multiple indications including specific cancers, particularly lymphomas and solid tumors where JAK2 has been shown to be up-regulated, and for cardiovascular diseases such as pulmonary hypertension.

For more information please contact:

    Mr Andrew Macdonald                      Dr Chris Burns
    Chief Executive Officer                  Director, Research
    T: +61 3 9208 4232                       T: +61 3 9208 4235
    E: andrew.macdonald@cytopia.com.au       E: chris.burns@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.

Website: www.cytopia.com.au

<
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cytopia Letter to Progen Shareholders
2. Cytopia and Other Progen Shareholders Maintain Call for Meeting
3. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
4. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
5. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
6. Bio-Matrix Scientific Group, Inc. Gets Updated Stock Recommendation By KonLin Investment Letter
7. Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
8. Boston Scientific Launches New Coronary Imaging Catheter
9. Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009
10. Moodys Raises Boston Scientifics Rating Outlook to Stable
11. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... N.Y., Aug. 1, 2011 Nycomed US Inc. ("Nycomed US") ... and Chief Executive Officer and member of the Board for ... the closing of the acquisition of Nycomed A/S by Takeda ... Bailey to the newly created position of Chief Operating Officer, ...
... a biopharmaceutical company pioneering a novel class of ... an entirely new class of naturally occurring human ... of these naturally supercharged human proteins enable biologic ... cells. This new class of proteins is the ...
... in the body, then alarm bells start ringing. ... disease and type 2 diabetes, formerly called adult-onset diabetes. ... then they might be able to treat such diseases ... colleagues at the Helmholtz-Zentrum Dresden-Rossendorf and the university in ...
Cached Biology Technology:Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 2Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 3Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 2Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 3In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3
(Date:7/9/2014)... Tampa, Fla. (July 9, 2014) Emerging fungal ... any other parasitic group, causing population declines of ... from the University of South Florida published in ... amphibians can acquire behavioral or immunological resistance to ... population declines. , "Acquired resistance is important ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... replace lost teeth with titanium dental implants could be improved. ... at micro level but also at nano level, researchers at ... method that could shorten the healing time for patients. , ... conductivity of the implant allows us to affect the body,s ...
... new type of cell in the immune system. ... belongs to a family of T-cells that play a critical ... could ultimately lead to the development of novel drugs that ... It is also potentially significant for many other ...
... 2011 Numera, a leading provider of innovative ... entered into a strategic partnership with HealthTrio LLC. ... integrate objective, biometric information from dozens of consumer-preferred ... Health Record (PHR). This new functionality will be ...
Cached Biology News:Healing times for dental implants could be cut 2New cell type offers immunology hope 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 3